Cargando…
Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
Aim. This study compared the effects of telmisartan and losartan on nonalcoholic fatty liver disease (NAFLD) and biochemical markers of insulin resistance in hypertensive NAFLD patients with type 2 diabetes mellitus. Methods. This was a randomized, open-label, parallel-group comparison of therapy wi...
Autores principales: | Hirata, Takumi, Tomita, Kengo, Kawai, Toshihide, Yokoyama, Hirokazu, Shimada, Akira, Kikuchi, Masahiro, Hirose, Hiroshi, Ebinuma, Hirotoshi, Irie, Junichiro, Ojiro, Keisuke, Oikawa, Yoichi, Saito, Hidetsugu, Itoh, Hiroshi, Hibi, Toshifumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755443/ https://www.ncbi.nlm.nih.gov/pubmed/23997767 http://dx.doi.org/10.1155/2013/587140 |
Ejemplares similares
-
Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”
por: Hirata, Takumi, et al.
Publicado: (2014) -
Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome
por: Vitale, Cristiana, et al.
Publicado: (2005) -
Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model
por: Graus-Nunes, Francielle, et al.
Publicado: (2019) -
Effects of telmisartan and losartan treatments on bone turnover
markers in patients with newly diagnosed stage I hypertension
por: Aydoğan, Berna İ, et al.
Publicado: (2019) -
Risk of myocardial infarction, heart failure, and cerebrovascular disease with the use of valsartan, losartan, irbesartan, and telmisartan in patients
por: Yoo, Yung-Geun, et al.
Publicado: (2023)